Close Menu

NEW YORK – Thermo Fisher Scientific and Daiichi Sankyo said today that they have partnered to develop a companion diagnostic for patients with non-small cell lung cancer (NSCLC).

The assay will use Thermo Fisher's Oncomine Dx Target sequencing test. It will be designed to identify NSCLC patients with mutations in HER2 who may be eligible for treatment with Enhertu (DS-8201), a HER2-directed antibody-drug-conjugate under development at Daiichi that is currently being tested in Phase II for HER2-mutated or HER2-overexpressing NSCLC.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.